Your browser doesn't support javascript.
loading
Creation of nano eye-drops and effective drug delivery to the interior of the eye.
Ikuta, Yoshikazu; Aoyagi, Shigenobu; Tanaka, Yuji; Sato, Kota; Inada, Satoshi; Koseki, Yoshitaka; Onodera, Tsunenobu; Oikawa, Hidetoshi; Kasai, Hitoshi.
Affiliation
  • Ikuta Y; Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
  • Aoyagi S; Ouchi Shinko Chemical Industrial Co., Ltd., Research and Development Center, 111 Shimojyukumae, Sukagawa, Fukushima 962-0806, Japan.
  • Tanaka Y; Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
  • Sato K; Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
  • Inada S; Ouchi Shinko Chemical Industrial Co., Ltd., Research and Development Center, 111 Shimojyukumae, Sukagawa, Fukushima 962-0806, Japan.
  • Koseki Y; Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
  • Onodera T; Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
  • Oikawa H; Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
  • Kasai H; Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
Sci Rep ; 7: 44229, 2017 03 14.
Article in En | MEDLINE | ID: mdl-28290486
ABSTRACT
Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-sized materials from the outside. In this work, we describe the utility of nano eye-drops utilising brinzolamide, a commercially available glaucoma treatment drug, as a target compound. Fabrication of the nanoparticles of brinzolamide prodrug increases the eye penetration rate and results in high drug efficacy, compared with that of commercially available brinzolamide eye-drops formulated as micro-sized structures. In addition, the resulting nano eye-drops were not toxic to the corneal epithelium after repeated administration for 1 week. The nano eye-drops may have applications as a next-generation ophthalmic treatment.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ophthalmic Solutions / Sulfonamides / Thiazines / Prodrugs / Drug Delivery Systems / Epithelium, Corneal / Nanoparticles Limits: Animals Language: En Journal: Sci Rep Year: 2017 Document type: Article Affiliation country: Japan Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ophthalmic Solutions / Sulfonamides / Thiazines / Prodrugs / Drug Delivery Systems / Epithelium, Corneal / Nanoparticles Limits: Animals Language: En Journal: Sci Rep Year: 2017 Document type: Article Affiliation country: Japan Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM